Laboratoires Servier

Notable products: • Gliclazide (Diamicron, Diamicron MR) — antidiabetic drug • Indapamide (Fludex SR, Natrilex SR, Lozide) — diuretic • Ivabradine (Procoralan) • Perindopril (Coversyl) — ACE inhibitor • Strontium ranelate (Protelos) — osteoporosis agent • Amineptine (Survector, Maneon, Directim) • Tianeptine (Stablon) • Trimetazidine (Vastarel MR) — antianginal drug. Other products: • Agomelatine (Valdoxan, Melitor, Thymanax) • Almitrine (Duxil, Vectarion) • Benfluorex (Mediaxal) • Carbutamide (Glucidoral) • Daflon 500 • Fenspiride (Pneumorel) • Fotemustine (Muphoran) • Fusafungine (Locabiotal) • Gliclazide (Diamicron) • Indapamide (Natrilix, Tertensif, Lozide) • Pegaspargase (Oncaspar) — Acute lymphoblastic leukemia treatment • Perindopril (Coversyl, Prestarium) • Perindopril/indapamide (Preterax, Coversyl Plus) • Piribedil (Trivastal retard) • Rilmenidine (Hyperium) • Tianeptine (Coaxil, Stablon) • Sodium alginate (Pseudophage) • Sulbutiamine (Arcalion) • Tertatolol (Artex) • Vitamins (Vitathion) ==Collaborative research==

As well as internal research and development activities, Servier undertakes publicly funded collaborative research projects with industrial and academic partners. One example, in the area of non-clinical safety assessment, is the InnoMed PredTox. The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission. In addition to these, Servier engages in research and licensing collaborations across the pharmaceutical and biotechnology industry. These collaborations include: • In Cardiology: XENTION (UK, 2013), AMGEN (USA, 2013), MIRAGEN (USA, 2011), ARMGO (USA, 2006) • In Diabetes: INTARCIA (USA, 2014) • In Metabolic diseases: INTERCEPT - TGR5 agonists (USA, 2011), Genfit (FR, 2004) • In Neurology (MS): GENEURO (CH, 2014) • In Oncology: CTI BIOPHARMA (USA, 2014), NOVARTIS (CH, 2014), CELLECTIS (FR, 2014), NERVIANO (IT, 2013), EOS (IT) / CLOVIS (USA, 2012), BIOINVENT (SE, 2012), MACROGENICS (USA, 2011/12), GALAPAGOS (NDL, 2011), BIOREALITES (FR, 2011), PHARMACYCLICS - HDAC inhibitor (USA, 2009), HYBRIGENICS (FR, 2007/2011) VERNALIS (UK, 2007/2011) • In Orphan Diseases/Cardiology/Diabetes: XOMA (USA, 2010) • In Osteoporosis & Osteoarthritis: OSTEOLOGIX (USA, 2010), GALAPAGOS (NDL, 2010), KAROS (USA, 2010), NORDIC BIOSCIENCE (DK, 2006/2010) Servier acquired Symphogen in 2020. == Controversy ==

Servier Laboratories has been the subject of worldwide scandal for creating and distributing a weight-loss drug called Mediator (Benfluorex), which may have killed up to 2,100 people. The movie 150 Milligrams, by director Emmanuelle Bercot, features Dr. Irène Frachon discovering that Mediator pills cause heart valve problems/deaths and how in 2009 she starts an uphill battle against the producer and the French health authorities. In March 2021, Servier was sentenced to a fine of 2.7 million euros for aggravated deception and involuntary manslaughter, however it was acquitted of fraud charges. The court also ordered the company to pay several hundred million euros in damages to the 6,500 plaintiffs, and one of its leading managers was sentenced to four years on probation. The French medical agency ANSM was fined 300,000 euros for failing proper supervision. A French pharmaceutical company, continued its operations in Russia despite international sanctions and the geopolitical consequences of Russia's invasion of Ukraine. The company's decision to maintain its presence in the region was criticized by organizations advocating for ethical corporate conduct during global conflicts. ==References==